

## Who can administer

May be administered by registered competent doctor or nurse/midwife

## Important information

- **Crystallisation** may occur - see under 'storage requirements' for further information
- See 'Monitoring requirements' below
- **Flush line with Glucose 5%** as there is a risk of precipitation with Sodium chloride 0.9% <sup>(ref 1)</sup>
- Administer via central line or large peripheral vein
- **Extravasation** causes inflammation and thrombophlebitis

## Available preparations

Mannitol 10% 500mL infusion (50g in 500mL)

Mannitol 15% 500mL infusion (75g in 500mL)

Mannitol 20% 500mL infusion (100g in 500mL) (this product may not be available- it has been discontinued by some manufacturers)

## Reconstitution

Already in solution

## Infusion fluids

Not required - product ready for infusion

## Methods of intravenous administration

### **Slow intravenous injection (test dose for patients with marked oliguria or suspected inadequate renal function)**

- **Test dose** over 3 to 5 minutes

### **Intermittent intravenous infusion**

- See under 'dose' for details
- Administer via a giving set that incorporates a 15 micron **in-line filter** <sup>(ref 1)</sup> - check packaging of administration set for details)- see photo



- The rate of infusion is usually adjusted to maintain a urine flow of at least 30 to 50mL/hour
- In emergency situations, the maximum infusion rate can be as high as 0.2g/kg over five minutes

## Dose in adults

<b>Volume in ml of Mannitol solution required</b>							
	<b>Required dose</b>	<b>15g</b>	<b>25g</b>	<b>50g</b>	<b>75g</b>	<b>100g</b>	<b>150g</b>
<b>10% solution</b>		<b>150ml</b>	<b>250ml</b>	<b>500ml</b>	<b>750ml</b>	<b>1000ml</b>	<b>1500ml</b>
<b>15% solution</b>		<b>100ml</b>	<b>167ml</b>	<b>333ml</b>	<b>500ml</b>	<b>667ml</b>	<b>1000ml</b>
<b>20% solution</b>		<b>75ml</b>	<b>125ml</b>	<b>250ml</b>	<b>375ml</b>	<b>500ml</b>	<b>750ml</b>

### **Reduction of intracranial pressure, cerebral volume and intraocular pressure**

- Usual dose: 1.5 to 2g/kg infused over 30 to 60 minutes (some references suggest a range of 0.25 to 2g/kg <sup>(ref 2)</sup>)
- Dose may be repeated once or twice after 4 to 8 hours <sup>(ref 2)</sup>
- See table above for guidance on the different volumes of mannitol required (depending on concentration)
- When used pre-operatively, the dose should be administered 60 to 90 minutes before surgery to obtain the maximum effect

### **Use in patients with oliguria or renal impairment**

- A test dose (to assess renal function) of about 0.2g per kg should be administered over three to five minutes - this should produce a diuresis of at least 30 to 50ml/hour during the next two to three hours
- A second test dose may be given if there is inadequate response to the first test dose
- See table above for guidance on the different volumes of mannitol required (depending on concentration)
- If the second test dose does not produce an adequate urine output, then need to reassess management

### **Acute renal failure**

- The general dose range for adults is 50 to 200g mannitol in a 24 hour period, with a dosage limit of 50g mannitol on any one occasion
- In most instances, adequate response will be achieved at a dosage of 50 to 100g mannitol per day
- The rate of administration is usually adjusted to maintain a urine flow of at least 30 to 50mL/hour
- See table above for guidance on the different volumes of mannitol required (depending on concentration)

### **Promotion of elimination of renally excreted toxic substances in poisoning**

- An initial loading dose of 25g may be given
- Adjust dose to maintain urinary output of at least 100ml/hour and positive fluid balance of 1 to 2 litres
- See table above for guidance on the different volumes of mannitol required (depending on concentration)

### **Renal impairment**

- Use with caution in severe renal impairment
- If the second test dose does not produce adequate urine output, reassess options

## **Monitoring**

- Renal function, fluid balance, serum electrolytes, serum and urine osmolality
- Monitor central venous pressure
- Assess cardiac function before and during treatment

## **Storage**

- Store between 20 and 30<sup>0</sup>C <sup>(ref 1)</sup>
- Do not refrigerate or freeze
- Solutions may crystallise, especially if stored at low temperatures
- The administration set should contain a **15 micron in-line filter** - see under method of administration above

### **Crystals may be redissolved by warming before use as follows:**

- Re-dissolve any crystals by warming to 37<sup>0</sup>C (Baxter products), or 60<sup>0</sup>C (Fresenius Kabi products) <sup>(ref 1)</sup>
- Use of dry heat (eg warming cabinet) is recommended - solutions should not be heated in water due to risk of contamination
- Shake vigorously occasionally <sup>(ref 1)</sup>
- Microwave heating **should not be used**
- The product should be allowed to cool to 37<sup>0</sup>C before infusion

## **References**

SPC March 2019

1. Injectable medicines administration guide, Medusa Accessed online 7th July 2023
2. BNF- accessed online 7th July 2023

## **Therapeutic classification**

Osmotic diuretic